CIRM Funded Clinical Trials
A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC
A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC
Steven Dubinett
Disease Area:
Investigator:
Institution:
CIRM Grant:
Award Value:
$10,955,315
Trial Sponsor:
University of California, Los Angeles
Trial Stage:
Phase 1
Trial Status:
Recruiting
Targeted Enrollment:
24
ClinicalTrials.gov ID:
Details:
The five-year survival rate for people diagnosed with the most advanced stage of non-small cell lung cancer (NSCLC) is between one and 10 percent.
To address this devastating condition, UCLA researchers are genetically modifying a patient’s own dendritic cells – key cells of the immune system – to boost their ability to stimulate native T cells - a type of white blood cell - to destroy cancer cells.
The investigators will combine this cell therapy with the FDA-approved therapy pembrolizumab (better known as Keytruda) a therapeutic that renders cancer cells more susceptible to clearance by the immune system.
Design:
Dose escalation and expansion.
Goal:
Determination of maximum tolerated dose and objective response rate at selected dose in lung cancers.
News about this clinical trial:
